Objective: To determine whether single nucleotide polymorphisms (SNPs) in TLR1 are associated with mortality, specifically sepsis-associated mortality, in a traumatically injured population. Background: Innate immune responses mediated by toll-like receptors (TLRs) induce early inflammatory responses to pathogen and damageassociated molecular patterns. Genetic variation in TLRs has been associated with susceptibility and outcomes in a number of infectious and noninfectious disease states. Methods: Patients admitted to the trauma intensive care unit at a level 1 trauma center serving 4 states were enrolled and followed for development of infection, sepsis, and death. Genomic DNA was genotyped and logistic regression analysis was performed to determine associations between TLR1 SNPs and mortality. We further examined for associations between TLR1 SNPs and mortality in subgroups on the basis of the presence of sepsis and the type of sepsis-associated organism. Results: We enrolled 1961 patients. TLR1 −7202G (rs5743551) was associated with increased mortality after traumatic injury and this association was primarily observed in the subset of patients who developed sepsis [adjusted odds ratio (OR): 3.16; 95% confidence interval (CI): 1.43-6.97, P = 0.004]. This association persisted after further restriction to gram-positive sepsis. TLR1 742A/G(Asn248Ser) (rs4833095), a coding SNP in LD with TLR1 −7202G , was also associated with mortality in gram-positive sepsis (adjusted OR: 4.16; 95% CI: 1.22-14.19, P = 0.023). Conclusions: Genetic variation in TLR1 is associated with increased mortality in patients with sepsis after traumatic injury and may represent a novel marker of risk for death in critically injured patients.
One example of this paradigm involves the gene for toll-like receptor 1 (TLR1). Two SNPs in TLR1 (TLR1 −7202A/G [rs5743551] and TLR1 1804G/T [rs5743618]) have previously been shown to confer higher innate immune inflammatory responses to Pam3CysSerLys4 (Pam3CSK4), a synthetic analog of bacterial lipoproteins and specific ligand for TLR1/TLR2 heterodimers. 1 These SNPs have also been associated with higher mortality, worse organ dysfunction, and higher prevalence of gram-positive infection in sepsis cases in a cohort of patients admitted to an intensive care unit (ICU) with primarily nonsurgical illness. 1 In patients with traumatic or thermal injury, candidate gene studies have linked other components of the innate immune system with risk of sepsis and mortality, including lipopolysaccharidebinding protein, toll-like receptor 4 (TLR4), and tumor necrosis factor α. 3, 7, 8 In addition to their role in host defense through the recognition of pathogen-associated molecular pattern responses, TLRs have also been shown to recognize endogenous ligands that are released in response to cellular necrosis or tissue damage. These endogenous activators are termed "damage-associated molecular patterns" and have been implicated in a wide variety of clinical illnesses (reviewed in Ref. 9, 10 ) including hemorrhagic shock in trauma. 11, 12 Thus, variation in genes of innate immunity could influence outcomes in critically injured patients in various ways. In the study reported here, we sought to determine whether SNPs in TLR1 are associated with mortality in patients who have been traumatically injured. Specifically, because TLR1 is thought to be involved in the innate immune response to infection through the recognition of pathogen-associated molecular patterns, 13, 14 we sought to identify associations between SNPs in TLR1 and sepsis-associated mortality after traumatic injury. We also examined whether variants in TLR1 might have a differential effect in the presence of gram-positive sepsis given that prior reports have associated TLR1 variants with increased prevalence of gram-positive infection. 1 The results presented here show that variation in TLR1 may play a role in modulating risk of death in trauma-related sepsis.
METHODS

Patient Recruitment, Data Collection, and Definitions
Injured patients admitted to the trauma ICU at Harborview Medical Center in Seattle, Washington, were enrolled during the period of August 2003 to December 2005 with approval of the institutional review board. Demographic and clinical data were collected from the electronic medical record and the trauma registry as previously described. 8 A patient was classified as severely injured if his or her injury severity score (ISS) was 16 or more. Severe head, thoracic, or abdominal traumatic injury was defined as an abbreviated injury scale (AIS) score of 3 or more. Incident cases of sepsis were identified through chart abstraction according to the guidelines of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Committee.
cultures from blood, urine, lower respiratory tract, tissue, catheter tips, cerebral spinal fluid, and wounds were considered clinically significant if the quantitative count of the culture was more than 100,000 colony forming units (CFU)/mL for urine and more than 10,000 CFU/mL for lower respiratory tract, or if a true quantitative count was unavailable, a value of 2+ or greater as reported by our laboratory. For patients with multiple cultures, we used the first significant culture of gram-positive and/or non-gram-positive organisms occurring after admission to the ICU. Patients were classified as having acute respiratory distress syndrome (ARDS) if they had acute onset of a PaO 2 /FiO 2 ≤ 200, bilateral infiltrates consistent with pulmonary edema on chest radiograph, the need for positive pressure ventilation via endotracheal tube, and no clinical evidence of left atrial hypertension, all occurring within the same 24-hour interval. Patients were classified as having acute kidney injury (AKI) if they met stage 2 or 3 Acute Kidney Injury Network criteria. 16 
Genotyping
We genotyped 3 SNPs in TLR1 in a blinded fashion, TLR1 −7202A/G (rs5743551) found in the 5 noncoding region, TLR1 1804G/T (Ser602Ile) (rs5743618) found adjacent to the predicted transmembrane domain, and TLR1 742A/G (Asn248Ser) (rs4833095), a nonsynonymous SNP within the extracellular domain of TLR1. These SNPs were chosen on the basis of existing literature indicating associations with outcomes in critically ill patients. Genotypes were determined by TaqMan-based real-time polymerase chain reaction for rs5743551 and rs4833095 as previously described. 17 Genotyping for rs5743618 used a restriction fragment length polymorphism introduced by this SNP. Briefly, a 1334 bp fragment containing this SNP was amplified from genomic DNA and then digested with the restriction enzyme PstI (Thermo Scientific), and the resulting fragments were visualized by gel electrophoresis; "GG" subjects were expected to have 2 bands at 457bp and 877bp, "TT" subjects were expected to have a single band at 1334bp, and "GT" subjects were expected to have all 3 bands. We included technical replicates on approximately 2% of samples.
Statistical Analysis
Categorical data are presented as counts and percentages. Continuous data are presented as medians and interquartile ranges. Categorical data were compared by χ 2 analysis and continuous data were analyzed using Student t test. For each comparison, the exact P values are reported and were considered significant if P < 0.05. Observed genotype frequencies were compared with expected frequencies to test for deviations from Hardy-Weinberg equilibrium.
The primary outcome for this study was in-hospital mortality. The secondary analyses included sepsis-associated mortality, susceptibility to sepsis, sepsis severity, ARDS in sepsis, AKI in sepsis, and gram-positive sepsis-associated mortality. We used multiple logistic regression analysis to test for associations between TLR1 genotypes and mortality. We tested recessive and codominant models that were adjusted for identified confounding variables of age, ISS, head AIS, and blood transfusion. Given that we tested 2 different models per genotype, we assigned statistical significance to tests achieving P < 0.025. We carried out these analyses in the entire cohort and subgroups of patients with or without sepsis and with or without grampositive sepsis. To minimize the risk of confounding due to racial differences in SNP frequency, we limited our analysis to white patients. Data were analyzed using Stata 12 Statistical Software (StataCorp LP; College Station, TX). A power analysis was performed using CaTS power calculator from the University of Michigan Center for Statistical Genetics (http://csg.sph.umich.edu/).
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RESULTS
Demographics and Clinical Outcomes
A total of 1961 subjects were enrolled and genotyped. Of these, 1498 (77%) were whites and were included in our analysis. Demographic and outcomes data for these patients are summarized in Table 1 . The majority of patients (70%) were male. The most common cause of injury was blunt trauma occurring in 1341 patients (90%). The majority of patients were severely injured, with a median ISS of 22 (interquartile range, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . Median ICU length of stay was 5 days (2-12) and median hospital length of stay was 12 days > (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . Sepsis developed in 691 patients (46%), with 316 patients developing severe sepsis or septic shock (21%).
A power analysis was performed post hoc, and we estimated that using a recessive model our study would have adequate statistical power (1 − β > 0.8) to detect a strong association with sepsisassociated mortality [odds ratio (OR) ≥ 2.8], with SNPs having a minor allele frequency of more than 0.2. Assuming a codominant model, we would have adequate power to detect a moderate association (OR ≥ 1.5), with SNPs having a minor allele frequency of more than 0.2.
Clinical Risk Factors for Mortality
In-hospital mortality was 10% (151 patients). Compared with those who survived, those who died were older, had higher ISSs, higher head AIS scores, and had more blood transfusions (P < 0.001); these identified covariates were subsequently used in our multiple logistic regression analysis and are summarized in Table 2 . Sepsis-associated mortality was 5.5% (83 patients). There were no differences in rates of laparotomy, thoracotomy, or operative fracture fixation between the patients with sepsis who died and those who survived (data not shown). There were a total of 4313 positive cultures recorded for the 1961 subjects; most subjects had more than 1 positive culture during their hospital stay. Among the subjects who developed sepsis, there were 523 with clinically significant cultures; 371 patients had cultures of gram-positive organisms (54% of patients with sepsis); and 342 patients had cultures of gram-negative organisms (49% of patients with sepsis). For the gram-positive cultures, the most common microorganism identified was Staphylococcus aureus and the most common source of the culture was the lower respiratory tract. A summary of the clinically significant gram-positive infections by species and source for the patients with sepsis can be found in Supplemental Digital Content Table 1 , available at: http://links.lww.com/SLA/A351. For the gram-negative cultures, the most common microorganism identified was Escherichia coli and the most common source was again the lower respiratory tract. A summary of the clinically significant gram-negative culture data for the patients with sepsis can be found in Supplemental Digital Content Table 2 , available at: http://links.lww.com/SLA/A351.
TLR1 SNPs Are Associated With Higher Mortality After Traumatic Injury
TLR1 −7202A/G was successfully genotyped in 1426 patients (95%) and TLR1 1804G/T was genotyped in 1406 patients (94%). The genotype frequencies of both SNPs were consistent with HardyWeinberg equilibrium (Table 3) . Table 3 illustrates the SNP genotype frequencies according to survival status. After adjusting for age, ISS, head AIS, and packed red blood cell transfusion, we found an association between TLR1 −7202G and in-hospital mortality when we assumed a recessive effect of the allele (adjusted OR, 2.41; P = 0.006). We did not see a significant association between homozygosity for TLR1 1804T and in-hospital mortality (OR, 1.68; P = 0.06). Using a codominant model, we saw an association between TLR1 −7202G and in-hospital mortality (OR, 1.46; P = 0.01) and again we did not see an association between TLR1 1804T and in-hospital mortality (data not shown). In subsequent analyses, we assumed a recessive effect of the variants on the phenotype because that is where we saw the strongest associations, consistent with prior reports.
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TLR1 SNPs Are Associated With Higher Mortality With Sepsis After Traumatic Injury
Given the role TLR1 is thought to play in the innate immune response to infection, we next investigated the degree to which associations between genetic variation in TLR1 and trauma-related mortality persisted when the analysis was restricted to patients who developed sepsis. Table 4 illustrates the SNP genotype frequencies in patients with sepsis according to their survival status. We found an association between homozygosity for TLR1 −7202G and mortality with sepsis (adjusted OR, 3.16; P = 0.004) and between homozygosity for TLR1 1804T and mortality with sepsis (OR, 2.48; P = 0.008). Notably, we observed no significant association between TLR1 genetic variation and mortality in patients without sepsis (Supplemental Digital Content Table 3 , available at: http://links.lww.com/SLA/ A351). In addition, we did not identify associations between any of the TLR1 polymorphisms and susceptibility to sepsis [adjusted risk for sepsis with TLR1 −7202A/G : 1.34 (95% CI: 0.85-2.10; P = 0.207) and for TLR1 1804G/T : 1.13 (95% CI: 0.78-1.64; P = 0.517) consistent with prior findings]. 1 In secondary analyses, we explored whether TLR1 variants were associated with common forms of organ dysfunction in sepsis, ARDS, and AKI. The incidence of ARDS in sepsis was 43.9% and the incidence of AKI in sepsis was 46.3%. We did not identify significant associations between the TLR1 polymorphisms and ARDS [adjusted risk for ARDS in sepsis with TLR1 −7202G : 1.53 (95% CI: 0.82-2.8; P = 0.178) and for TLR1 1804T : 1.21 (95% CI: 0.71-2.1; P = 0.486)] or AKI [adjusted risk for AKI in sepsis with TLR1 −7202G : 1.33 (95% CI: 0.71-2.5; P = 0.371) and for TLR1 1804T : 1.2 (95% CI: 0.7-2.1; P = 0.508)] in the patients with sepsis, although there were trends toward a higher incidence of ARDS and AKI in TLR1 −7202G and TLR1 1804T homozygotes (Table 5) .
TLR1 forms a heterodimer with TLR2 at the cell surface and this dimer is thought to specifically play a role in innate immune host responses to gram-positive infection. 13, 19, 20 In light of this biology, we next tested for associations between variation in TLR1 and mortality in patients with gram-positive sepsis. Three hundred fifty three (24.8%) of the 1394 patients genotyped for TLR1 −7202A/G had gram-positive sepsis. We identified a greater than 4-fold increased risk of death in gram-positive sepsis among TLR1 −7202G homozygotes (Table 6 , P = 0.013). For patients homozygous for TLR1 1804T , we did not identify an association with mortality in gram-positive sepsis. Of note, we found no association between any of the TLR1 genetic variations and mortality in patients with non-gram-positive sepsis (Supplemental Digital Content Table 4, available 
Nonsynonymous TLR1 SNP Is Associated With Mortality in Gram-Positive Sepsis
Given that we did not observe an association between TLR1 1804G/T , a nonsynonymous SNP, and mortality in gram-positive sepsis, we sought additional coding variations that might explain the association seen with TLR1 −7202A/G . The nonsynonymous SNP, rs4833095 [TLR1 742A/G (Asn248Ser) ], is in significant linkage disequilibrium (LD) (R 2 = 0.93) with TLR1 −7202A/G (Table 7) . TLR1 742A/G was genotyped in 1394 patients (93%, Table 8 ). Mortality in patients with gram-positive sepsis was significantly higher in patients who were homozygous for the rare versus common variant (26.3% vs 11.3%, P = 0.014). In the adjusted analysis, we observed a significant association of TLR1 742G with mortality in gram-positive sepsis (OR, 4.13, P = 0.023). event. Patients who survive the early time period after trauma are at risk of developing, and possibly dying from, sepsis and sepsisassociated multiple-organ dysfunction and failure. Sepsis after traumatic injury is associated with greater ICU and hospital length of stay, more ventilator days, increased incidence of multiple-organ failure, and increased in-hospital mortality compared with those who do not develop sepsis. Despite decreases in both the incidence of sepsis and the overall in-hospital mortality of trauma patients, the mortality in trauma patients with sepsis has not changed. 22 The finding of decreased incidence of sepsis and decreased mortality in trauma patients is likely the result of improved management in the early posttrauma period, increased understanding of clinical risk factors for sepsis in trauma patients, and resultant improvements in management of these patients overall. However, the persistent incidence of mortality in trauma-related sepsis remains a troubling problem. Recently, interest has turned to the potential role for genetic variation in altering host susceptibility to sepsis-related outcomes. In this study, we have addressed the question of whether genetic differences that affect leukocyte inflammatory response to bacterial products, and, potentially, damage-associated molecular patterns, might be associated with increased sepsis-related mortality in patients who have experienced major trauma.
The TLR1 −7202A/G SNP is located in the 5 untranslated region of the TLR1 gene on chromosome 4 at the −7202 position relative to the start codon. TLR1 1804G/T and TLR1 742A/G are both located in coding regions of the TLR1 gene. TLR1 1804G/T causes an amino acid change from serine to isoleucine in the region of the TLR1 protein that has been predicted to be in the transmembrane domain.
23 TLR1 742A/G causes an amino acid change from asparagine to serine in a region predicted to be in the extracellular domain. Both the TLR1 1804T and TLR1 742G variants are predicted to be benign by PolyPhen-2, 24 with scores of 0 and 0.001, respectively, and to be tolerated by SIFT 25 analysis with scores of 0.40 and 0.50, respectively.
TLR1 −7202G has been associated with a hypermorphic effects on innate immune inflammatory responses ex vivo and has been associated with higher mortality, organ dysfunction, and susceptibility to gram-positive infection in patients with severe sepsis.
1 TLR1 1804T is in high LD with TLR1 −7202G and has been shown to cause hyperresponsiveness to Pam 3 CSK 4 in transient transfection assays. Healthy carriers of the G allele have increased cell surface expression of TLR1 on peripheral blood monocytes. This polymorphism has also been associated with increased mortality in sepsis, 1 protective association against leprosy, 26 and protection from pyelonephritis. 27 TLR1 742A/G has been associated with circulatory dysfunction in sepsis and with pulmonary infection among patients with sepsis. 28 This same study also found that TLR1 −7202A/G and TLR1 1804G/T were associated with circulatory dysfunction in sepsis. In addition, TLR1 742A/G has been associated with increased susceptibility to malaria in pregnancy 29 and increased risk of IgA nephropathy in Korean children. 30 Taken together, these findings strongly suggest an important role for TLR1 in modulating host responses to infection.
Our study provides an important extension of previous associations between TLR1 SNPs and sepsis-related outcomes. In contrast to previous studies that used populations of patients primarily from medical ICUs for whom time of onset of sepsis is ill defined, this study used a traumatically injured cohort who suffered an inciting event at a known time and of a quantifiable severity. Thus, the interpretation of the observed associations is less likely to be influenced by unmeasured confounders. Furthermore, the initial inflammatory stimulus for most of these patients was noninfectious and, thus, we were able to test to what extent TLR1 polymorphisms may influence outcomes in the presence or absence of severe infection/sepsis. We were able to show that the positive association seen between TLR1 −7202A/G and mortality in critically ill patients who sustained traumatic injury was driven by the subset of patients who had gram-positive sepsis as we did not observe a significant association in patients without sepsis or those with non-gram-positive sepsis. This study is the first to suggest that TLR1 variants affect outcomes from primarily gram-positive sepsis.
We have an incomplete understanding of how TLR1 variants affect risk for death in patients with sepsis. In patients with sepsis from a medical ICU, TLR1 −7202G has been associated with less days free of organ dysfunction 28 and susceptibility to acute lung injury. 1 Although we did not identify an association between the TLR1 polymorphisms and development of ARDS or AKI in trauma-related sepsis, there was a trend toward a higher incidence of both forms of organ dysfunction among subjects homozygous for the rare variant (TLR1 −7202G ). The failure to detect a statistically significant association may be the result of the inadequate power to detect such a relationship. Larger studies in well-phenotyped populations with sepsis will be needed to better elucidate the antecedent events leading to death in patients homozygous for the TLR1 −7202G variant.
From a cellular and molecular standpoint, the large hypermorphic effect on innate immune inflammatory responses in human whole blood ex vivo that have been seen with TLR1 −7202G inflammation predisposing to death. Notably, ex vivo studies have shown that the effect of TLR1 −7202A/G is codominant whereas the clinical association with mortality in this study and in our prior report was recessive. In our association study, we observed a trend toward lower sepsis-associated mortality in the heterozygous state (Table 4) . These findings raise the possibility that the inflammation induced in the heterozygous state may be at least marginally beneficial and that a state of balancing selection might explain why this highly functional allele persists at such a high frequency in the population.
This study has some potential limitations. Although we have associated coding variants within TLR1 with trauma-related sepsis mortality, we have not definitively shown which variants within the LD block are necessary for the effect. Given that there exists extended LD within the TLR1 locus 31 and a gene cluster involving TLR6-TLR1-TLR10 on chromosome 4, 32 future studies in nonwhite or admixed populations will be necessary to more finely map the causative SNPs. In addition, the subgroup analyses testing for association between TLR1 variant and sepsis-related mortality by infection type were statistically underpowered. Furthermore, only the first clinically relevant positive culture of a gram-positive and/or gram-negative organism(s) was taken into account for this study but most patients had more than 1 positive culture during their hospital course. Therefore, it is possible that the first culture did not represent the causal microorganism for the development of sepsis. Despite these limitations, our findings are congruent with prior findings linking TLR1 −7202G to a higher prevalence of gram-positive infections in patients with sepsis and predominantly medical illnesses. 1 Larger prospective studies will be needed to accurately determine effect sizes in gram-positive sepsis and exclude significant associations in gram-negative sepsis.
In summary, we have identified an association between genetic variation in TLR1 and mortality in sepsis after severe traumatic injury. This study extends previous associations with TLR1 in patients with sepsis in predominantly nonsurgical patients. We have also found evidence that TLR1 variation may have effects on mortality that are specific to gram-positive infection. Future research will determine the mechanisms linking TLR1 to increased mortality and whether early testing for these genetic variants might drive changes in practice, such as more frequent surveillance cultures, timing and choice of prophylactic or empiric antibiotics, or use of novel therapeutic interventions modulating TLR1 function.
